| Ticker: DIGE | 2301-B Broadbirch Drive | |
| Exchange: NASDAQ-National Market | Silver Spring, Maryland 20904 | |
| Industry: Manufacturing | (301) 470-6500 |
| Type of Shares: | Common Shares | Filing Date: | 4/1/96 | |
| U.S. Shares: | 3,000,000 | Offer Date: | 5/22/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 3,000,000 | Offer Price: | $11.50 | |
| Secondary Shares: | 0 | Gross Spread: | $0.81 | |
| Offering Amount: | $36,000,000 | Selling: | $0.49 | |
| Expenses: | $800,000 | Reallowance: | $0.10 | |
| Shares Out After: | 11,276,408 |
| Manager | Tier | Phone |
| UBS Securities Inc. | Lead Manager | (212) 230-4000 |
| Montgomery Securities | Co-manager | 4156272220 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 6/30/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $6.16 | $4.76 | $4.45 | Assets: | $3.92 |
| Net Income: | -$1.51 | -$1.71 | $0.76 | Liabilities: | $18.62 |
| EPS: | -$0.18 | -$0.20 | Equity: | -$14.70 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company manufactures and markets DNA systems for the screening, monitoring and diagnosis of human diseases. The company's products are designed to help improve clinical outcomes and reduce the overall cost of disease management. The company's lead product, the Hybrid Capture HPV DNA test, detects the presence of human papillomavirus (HPV), the primary cause of cervical cancer, which is the second most common cancer among women worldwide. The company's HPV test for the follow-up screening of women with equivocal Pap smears is the only HPV test approved for marketing in the United States by the U.S. Food and Drug Administration. The company's objective is to establish its HPV test as the new standard of care for cervical cancer screening. The Company's HPV test is a rapid, accurate, objective and non-invasive method to screen omen for the presence of HPV. |
| Use of Proceeds |
| The proceeds from the offering will be used to expand sales and marketing, to fund increased research and development including clinical trials, debt repayment and for working capital and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.